Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results-Reference-Cited by-同舟云学术

Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results

Published:2023 Issue:2 Volume:123 Page:52
ISSN:1997-7298
Container-title:Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova
language:en
Short-container-title:Z. nevrol. psikhiatr. im. S.S. Korsakova

Author:

Boyko A.N.^ORCID,Bakhtiyarova K.Z.^ORCID,Boyko O.V.^ORCID,Dudin V.A.^ORCID,Zaslavskii L.G.^ORCID,Malkova N.A.^ORCID,Parshina E.V.^ORCID,Poverennova I.Ye.^ORCID,Sivertseva S.A.^ORCID,Totolyan N.A.^ORCID,Shchur S.G.^ORCID,Khabirov F.A.^ORCID,Goncharova Z.A.^ORCID,Zakharova M.N.^ORCID,Bolsun D.D.^ORCID,Zinkina-Orikhan A.V.^ORCID,Lin’kova Yu.N.^ORCID,Chernovskaya T.V.^ORCID,Porozova A.A.^ORCID

Publisher

Media Sphere Publishing Group

Subject

Psychiatry and Mental health,Neurology (clinical)

Reference10 articles.

1. The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis

2. History of modern multiple sclerosis therapy

3. New Life to an Old Treatment: Pegylated Interferon Beta 1a in the Management of Multiple Sclerosis

4. PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update

5. Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sampeginterferon beta-1a in clinical practice;Neurology, Neuropsychiatry, Psychosomatics;2024-08-07

2. Efficacy and Safety of PEGylated Interferons for Relapsing-Remitting Multiple Sclerosis in Adult Patients: Results of Matching-Adjusted Indirect Comparison;Annals of Clinical and Experimental Neurology;2024-04-05

3. Russian-Belarusian Expert Council “New opportunities in the treatment of patients with multiple sclerosis” (October 1, 2023). Main conclusions of the first meeting;Neurology, Neuropsychiatry, Psychosomatics;2023-12-17